膵臓がん

プレスリリース

学会レポート

局所進行膵がんの導入化学療法後の二次的切除によりOSを約2倍に延長【ESMO 2019】

2019-09-28
ESMO

Secondary Resectability Improved with Induction Chemotherapy in Locally Advanced Pancreatic Cancer

Conversion associated with significantly improved OS in the 165 patients in the intent-to-treat (ITT) population; OS was 27.4 months in patients who converted compared to 14.2 months in those who did not (p = 0.0035).